203 related articles for article (PubMed ID: 37480275)
1. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
3. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?
Schaefer R; Hernandez D; Selberg L; Schlander M
J Comp Eff Res; 2021 Nov; 10(16):1187-1195. PubMed ID: 34583534
[No Abstract] [Full Text] [Related]
5. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
8. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
[TBL] [Abstract][Full Text] [Related]
9. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
11. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
Chabot I; Rocchi A
Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
[TBL] [Abstract][Full Text] [Related]
13. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
14. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.
Shengnan D; Zixuan L; Na Z; Weikai Z; Yuanyuan Y; Jiasu L; Ni Y
Front Public Health; 2022; 10():964040. PubMed ID: 36187695
[TBL] [Abstract][Full Text] [Related]
15. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
16. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
[TBL] [Abstract][Full Text] [Related]
17. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
Thokala P; Carlson JJ; Drummond M
J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
[TBL] [Abstract][Full Text] [Related]
18. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.
Cherla A; Renwick M; Jha A; Mossialos E
EClinicalMedicine; 2020 Dec; 29-30():100625. PubMed ID: 33437948
[TBL] [Abstract][Full Text] [Related]
20. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
Linley WG; Hughes DA
Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]